Initiate Phase 2 trial of AT-1501 in islet cell transplantation
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Jan 2021
- Due
- 31 Mar 2021
- Checked
- 24 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initiate Phase 2 trial of AT-1501 in islet cell transplantation for type 1 diabetics in Q1 2021”
What we found
Evidence strength A What the grades mean
The company did not initiate the Phase 2 trial by the Q1 2021 deadline; subsequent filings indicate the trial was still in the planning or pre-enrollment stage well after the deadline.
-
A Eledon Pharmaceuticals, Inc. 8-K filed 2021-05-13
“we remain on track to initiate a Phase 2 trial of AT-1501 in islet cell transplantation” ✓ confirmed on the page
-
A Eledon Pharmaceuticals, Inc. 8-K filed 2021-05-13
“Enroll first patient in Phase 2 trial of AT-1501 in islet cell transplantation for type 1 diabetes with interim data readout expected in first half 2022.” ✓ confirmed on the page
Market reaction: the shares moved -13.1% against the S&P 500 over the three sessions around the disclosure (12 May 2021 to 17 May 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 2 trial of AT-1501
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Eledon Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ELDN-021029 · Corrections policy